GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » Enterprise Value

Evofem Biosciences (Evofem Biosciences) Enterprise Value : $44.17 Mil (As of May. 18, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Evofem Biosciences's Enterprise Value is $44.17 Mil. Evofem Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-17.85 Mil. Therefore, Evofem Biosciences's EV-to-EBIT ratio for today is -2.48.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Evofem Biosciences's Enterprise Value is $44.17 Mil. Evofem Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-16.07 Mil. Therefore, Evofem Biosciences's EV-to-EBITDA ratio for today is -2.75.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Evofem Biosciences's Enterprise Value is $44.17 Mil. Evofem Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $18.22 Mil. Therefore, Evofem Biosciences's EV-to-Revenue ratio for today is 2.42.


Evofem Biosciences Enterprise Value Historical Data

The historical data trend for Evofem Biosciences's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences Enterprise Value Chart

Evofem Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 273.36 233.12 173.71 76.24 44.65

Evofem Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.24 59.59 45.06 43.94 44.65

Competitive Comparison of Evofem Biosciences's Enterprise Value

For the Biotechnology subindustry, Evofem Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evofem Biosciences's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Enterprise Value falls into.



Evofem Biosciences Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Evofem Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Evofem Biosciences's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evofem Biosciences  (OTCPK:EVFM) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Evofem Biosciences's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=44.172/-17.847
=-2.48

Evofem Biosciences's current Enterprise Value is $44.17 Mil.
Evofem Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.85 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Evofem Biosciences's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=44.172/-16.066
=-2.75

Evofem Biosciences's current Enterprise Value is $44.17 Mil.
Evofem Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.07 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Evofem Biosciences's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=44.172/18.218
=2.42

Evofem Biosciences's current Enterprise Value is $44.17 Mil.
Evofem Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evofem Biosciences Enterprise Value Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Evofem Biosciences (Evofem Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Executives
Yan Zhang officer: Chief Financial Officer 6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar director, 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip director 12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca officer: Chief Commercial Officer 12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier director, officer: Chief Executive Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick officer: General Counsel and Secretary 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File officer: Chief Financial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans officer: Chief Commercial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd. 10 percent owner 1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd 10 percent owner 65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp 10 percent owner 767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell officer: Chief Medical Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130